Insider Selling: Charles River Laboratories International, Inc. (CRL) Director Sells 10,227 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director C Richard Reese sold 10,227 shares of the stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total value of $1,047,244.80. Following the sale, the director now owns 51,444 shares in the company, valued at $5,267,865.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Charles River Laboratories International, Inc. (NYSE:CRL) traded up $0.65 on Friday, reaching $103.13. The company had a trading volume of 250,700 shares, compared to its average volume of 378,407. Charles River Laboratories International, Inc. has a 12-month low of $72.07 and a 12-month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. The firm has a market cap of $4,853.61, a PE ratio of 20.13, a P/E/G ratio of 1.63 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The firm had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. During the same period last year, the firm earned $1.18 EPS. The firm’s revenue was up 9.0% compared to the same quarter last year. equities analysts predict that Charles River Laboratories International, Inc. will post 5.13 EPS for the current fiscal year.

A number of analysts have recently weighed in on CRL shares. Credit Suisse Group reiterated a “neutral” rating and set a $112.00 price target (up from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research report on Tuesday, October 24th. ValuEngine cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Jefferies Group reiterated a “buy” rating and set a $120.00 price target on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $106.63.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. YorkBridge Wealth Partners LLC boosted its stake in Charles River Laboratories International by 445.5% during the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Charles River Laboratories International by 69.0% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 548 shares in the last quarter. Advisor Group Inc. boosted its stake in Charles River Laboratories International by 159.4% during the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 945 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories International by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares in the last quarter. Finally, Riverhead Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after acquiring an additional 247 shares in the last quarter. Hedge funds and other institutional investors own 96.27% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Charles River Laboratories International, Inc. (CRL) Director Sells 10,227 Shares of Stock” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/12/08/insider-selling-charles-river-laboratories-international-inc-crl-director-sells-10227-shares-of-stock.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply